- Home
- Drafting and Negotiating Clinical Trial Agreements
Drafting and Negotiating Clinical Trial Agreements Training Course
This intensive and interactive one-day programme focuses on CTAs in the pharmaceutical industry where legal, policy and ethical considerations underpin how these agreements are drafted
Details
Why you should attend
The life science sector is heavily regulated and CTAs are some of the most important agreements for companies operating in this sector. Having appropriate CTAs in place is therefore essential for managing relationships between the different stakeholders, and apportioning risk and responsibilities between them. If appropriate contractual arrangements are not in place, a clinical trial may not receive approval or issues may arise with the integrity or validity of the data collected. Further, disputes between the parties can arise if responsibilities are not clearly defined in the agreement.
This intensive and interactive one-day programme focuses on CTAs in the pharmaceutical industry where legal, policy and ethical considerations underpin how these agreements are drafted. Participants will receive an overview of the legal framework regulating clinical trials in the European Union (and UK), before taking a closer, comprehensive look at specific issues that must be considered when drafting a CTA. Using a case study, participants will also look at some example clauses and will have the opportunity to practise negotiation skills in the safe environment of the course room under the guidance of our expert faculty.
By the end of the programme, you will be more confident in spotting and addressing the key issues that arise when negotiating and drafting CTAs, understand how best to mitigate against the risks and deal with them effectively when they do arise.
Key topics covered in this intensive and interactive seminar:
- An overview of the legal, ethical and policy considerations that underpin the conduct clinical trials as these affect how the terms of clinical trials agreements are drafted
- Recognising and dealing with key commercial and regulatory issues (including in particular relating to Brexit and the “flexibilities” adopted during the pandemic) that arise when drafting clinical trials agreements
- Drafting and negotiating techniques to minimise disputes and maximise efficiency
Attending this seminar will enable you to:
- Understand the legal framework concerning clinical trials in the EU and the UK
- Recognise and address the issues that arise when drafting and negotiating CTAs
- Gain a better understanding of the commercial and regulatory issues that affect CTAs
- Consider the issues through the differing perspectives of sponsors and health care organisations
Who should attend?
This course will be particularly beneficial to:
- Contract managers
- Clinical contract specialists
- Clinical trial managers
- R&D staff
- Regulatory specialists
- Lawyers and in-house legal teams
- Legal executives
Programme
Overview of the regulation of clinical trials – the legal framework governing clinical trials in the EU and the UK
- What a clinical trial is and the types of clinical trial
- EU regulatory framework:
- The current Clinical Trials Directive (Directive 2001/20/EC)
- The new Clinical Trial Regulation (Regulation 536/2014/EU)
- UK framework post Brexit
- Who the stakeholders are and their roles and obligations
- Ethics approval and policy issues (eg NHS approval)
- What could happen if a clinical trial is not conducted in accordance with the law
Specific considerations relevant to the conduct of clinical trials
- Informed consent – what is it and why is it needed?
- Data protection – overview of the requirements, use of patient data during and after a clinical trial (particularly in light of the 3/2019 guidance from the European Data Protection Board)
- Product liability – what is the law (and crucially current practice) on product liability and the requirement of clinical trials insurance
- Confidentiality and intellectual property rights:
- the tension between principle of transparency and protecting confidential information
- protecting intellectual property rights
CASE STUDY: Drafting and negotiating CTAs – Part 1
- The anatomy of a CTA and some typical clauses and issues that might arise. We look at these issues from the perspective of each party and the negotiation tactics that could be used to reach an agreed position.
- Structure of a CTA (and the UK model CTAs updated in March 2020)
- Common sticking points in negotiation:
- Ownership and use of intellectual property
- Use of data generated during the trial
- Liabilities and insurance requirements for both parties
- Warranties and indemnities
- Manufacture and supply
- Disclosure of payments to healthcare professionals and healthcare organisations
- Freedom of information requests
- Termination and consequences of termination
PRACTICAL EXERCISE: Negotiation
This interactive session allows participants to practise negotiating specific clauses concerning liabilities and indemnities using skills and techniques to minimise disputes and maximise efficiency. Example clauses will be provided and considered within the group. Participants will be divided into small groups representing the opposite party to practise their negotiation skills.
CASE STUDY: Drafting and negotiating CTAs – Part 2
- Discussion of points arising from the negotiation exercise
- Standard contracts
- Practical tips
- Specific ideas arising from a very large contract with a CRO to whom the pharma company outsourced all of its clinical trial management requirements. Making the CRO de facto (and in a couple of cases de jure) sponsor.
Additional considerations relevant to drafting and negotiating CTAs
- Multi-jurisdictional trials
- The implications of Brexit
Presenter
Alex Denoon (More...)
Alex Denoon is head of the regulatory team at Bristows, primarily advising life sciences clients. He has more than 20 years’ experience advising clients in the sector. In addition to his LLB, Alex has a BSc in Human Genetics. Alex spent more than five years in-house, including as GC and Company Secretary of Biotech Australia. He works with clients to devise and implement regulatory strategies throughout the product life cycle of pharmaceuticals and medical devices, and has advised clients in relation to more challenging issues including: genomics, cell therapies, tissue and cells requirements, borderline products, combination products, 3D printing, healthcare apps and remote diagnostics, and has been involved in the development of a number of regulatory frameworks and guidelines.
In addition to a range of contentious (judicial review) and advisory matters, he has a breadth of international experience in structuring, negotiating and drafting commercial agreements. Alex is widely published and speaks regularly at conferences.
Book now
Book now
|
5 Nov 2021 Live webinar |
|||
|
5 Nov 2021 Live webinar |
GBP 599 499 EUR 859 719 USD 970 814 Until 1 Oct* |
Enrol now
to attend Live webinar |
|
|
24 Feb 2022 Live webinar |
|||
|
24 Feb 2022 Live webinar |
GBP 599 499 EUR 859 719 USD 970 814 Until 20 Jan 22* |
Enrol now
to attend Live webinar |
|
|
13 May 2022 Live webinar |
|||
|
13 May 2022 Live webinar |
GBP 599 499 EUR 859 719 USD 970 814 Until 8 Apr 22* |
Enrol now
to attend Live webinar |
|
|
1 Aug 2022 Face-to-face, (venue not yet confirmed) |
|||
|
1 Aug 2022 Face-to-face (venue not yet confirmed) |
GBP 699 599 EUR 979 839 USD 1,090 934 Until 27 Jun 22* |
Enrol now
to attend Face-to-face (venue not yet confirmed) |
|
|
4 Nov 2022 Live webinar |
|||
|
4 Nov 2022 Live webinar |
GBP 599 499 EUR 859 719 USD 970 814 Until 30 Sep 22* |
Enrol now
to attend Live webinar |
|
Learn more about our face-to-face and webinar training formats.
* Note the early booking discount cannot be combined with any other offers or promotional code